BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin M, Zhu M, Ge T, Lu N, Fu X, Chang J. Prognostic potential and mechanism of SORT1 and its co‐expressed genes in hepatocellular carcinoma based on integrative analysis of multiple database. Precision Medical Sciences 2022. [DOI: 10.1002/prm2.12084] [Reference Citation Analysis]
2 Liakina V, Strainiene S, Stundiene I, Maksimaityte V, Kazenaite E. Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. World J Hepatol 2022; 14(7): 1277-1290 [DOI: 10.4254/wjh.v14.i7.1277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Qin H, Yuan B, Huang W, Wang Y. Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances. Front Oncol 2022;12:924696. [DOI: 10.3389/fonc.2022.924696] [Reference Citation Analysis]
4 Huang H, Liao X, Zhu G, Han C, Wang X, Yang C, Zhou X, Liang T, Huang K, Peng T. Acyl-CoA Binding Domain Containing 4 Polymorphism rs4986172 and Expression Can Serve as Overall Survival Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Hepatectomy. PGPM 2022;Volume 15:277-300. [DOI: 10.2147/pgpm.s349350] [Reference Citation Analysis]
5 Lee HW, Park SY, Lee YR, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL. Am J Gastroenterol 2022;117:288-94. [PMID: 34506308 DOI: 10.14309/ajg.0000000000001497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mallaiah D, Chandramathi Shankar P, Vadde R. Nanoparticle-based theranostics and their role in hepatocellular carcinoma. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3 2022. [DOI: 10.1016/b978-0-323-99283-1.00019-7] [Reference Citation Analysis]
7 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yu J, Ma S, Tian S, Zhang M, Ding X, Liu Y, Yang F, Hu Y, Xuan G, Zhou X, Wang J, Han Y. Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes. Front Cell Dev Biol 2021;9:700553. [PMID: 34671598 DOI: 10.3389/fcell.2021.700553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zheng Y, Li Y, Feng J, Li J, Ji J, Wu L, Yu Q, Dai W, Wu J, Zhou Y, Guo C. Cellular based immunotherapy for primary liver cancer. J Exp Clin Cancer Res 2021;40:250. [PMID: 34372912 DOI: 10.1186/s13046-021-02030-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]